PARP inhibitors are a new form of targeted therapy that can stop cancer cells from repairing their damaged DNA, causing them to die. The FDA recently approved them for the treatment of BRCA-mutation related metastatic breast cancer. Those kinds of cancers are more likely to be triple negative breast cancer, which can be more aggressive. Recent data has shown that women who received PARP inhibitors did better overall than patients who received chemotherapy.
“This broadens our arsenal for the treatment of triple negative breast cancer beyond conventional chemotherapy,” says Dr. Heather McArthur, Medical Director of Breast Oncology at Cedars-Sinai Medical Center.
Learn more about SurvivorNet's rigorous medical review process.
Dr. Heather McArthur is Medical Director of Breast Oncology at Cedars-Sinai Medical Center in Los Angeles. Read More
PARP inhibitors are a new form of targeted therapy that can stop cancer cells from repairing their damaged DNA, causing them to die. The FDA recently approved them for the treatment of BRCA-mutation related metastatic breast cancer. Those kinds of cancers are more likely to be triple negative breast cancer, which can be more aggressive. Recent data has shown that women who received PARP inhibitors did better overall than patients who received chemotherapy.
“This broadens our arsenal for the treatment of triple negative breast cancer beyond conventional chemotherapy,” says Dr. Heather McArthur, Medical Director of Breast Oncology at Cedars-Sinai Medical Center.
Read More
